Certain types of university intellectual property can sometimes prove difficult to commercialise through traditional routes, usually because it is at an early stage of development, or because it presents enough uncertainty for companies to risk an investment.
University Technology’s Easy Access portal offers access to this type of intellectual property at no cost, to enable companies to evaluate it and put it to use quickly, with reduced risk.
Easy Access uses quick and simple licence agreements to fast-track the transfer of knowledge and expertise from Scotland’s universities to industry, so that these technologies may be developed for the benefit of the economy and society.
Through this initiative, our aim is to make it easier for Scottish universities and industry to work together and build strong, long-term relationships with industry partners.
Showing 1 - 10 of 24 opportunities
A novel therapeutic target for sickle cell disease and other haemolytic anaemias
A novel technology allowing targeting of cancer cells using the innate immune system
The neurodegenerative inherited disease Spinal Muscular Atrophy (SMA) is the leading genetic cause of infant mortality, affecting 1:6,000 live births. SMA causes a loss of spinal motor neurons and is characterised by progressive muscular atrophy.
A tetrazine small-molecule trigger for activating prodrugs has been developed. Active molecules, such as a therapeutic drug or imaging fluorophore, can be caged within a polymer nanoparticle for controlled release at a targeted site.
Novel compound series of phosphofructokinase allosteric inhibitors which show excellent efficacy in vitro against the parasite and in mouse models of the disease in vivo. The well characterised inhibitors of this novel trypanosomiasis target have the potential to fill the unmet need for safe, cheap,...
A novel approach shows promising results as a potential therapeutic for allergic conditions, including severe steroid resistant asthma. A peptide has been identified, HpARI, that inactivates and inhibits release of IL-33 a critical step in the development of allergic disease.
This anti-influenza therapy offers potential as anti-viral treatment as well as prevention against all major flu strains, including influenza A infection.
A host-directed diagnostic methodology, which uses only 30 μL of whole blood, and enables rapid and accurate detection of sepsis in neonates and other subjects. The test removes false negative results associated with current gold standard microbiological methods.
This new approach converts chemotherapy agents into prodrugs, significantly reducing systemic toxicity, and enabling local activation only at tumour sites where a specific catalyst, palladium, has been implanted.
Antibiotics are often prescribed inappropriately leading to (1) patients remaining infected and failing to recover from bacterial infection, and (2) the spread of bacterial antibiotic resistance. Our laboratory prototype devices can provide accurate detection and quantification of bacterial suscepti...
Please select the market sector you are interested in.
Please select the university you are interested in.
Show only Easy Access opportunities.
Narrow your search with a few keywords.
Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities